Loading…
Loading…
The PLI Scheme for Bulk Drugs is a discretionary incremental-sales subsidy operated by the Department of Pharmaceuticals (DoP) with IFCI Ltd as the designated Project Management Agency (PMA). Eligible applicants commit to greenfield manufacturing capacity for one or more of 41 specified critical KSM/DI/API products and, in return, receive incentives calculated as a percentage of incremental sales over the base year (FY 2019-20 or first year of commercial production).
| Target segment | Domestic value-add floor | Incentive rate | Tenure |
|---|---|---|---|
| Key Fermentation-based (KSMs/DIs) | ≥ 90% | 20% (Y1-Y4), 15% (Y5), 5% (Y6) | 6 years |
| Niche Fermentation-based (APIs) | ≥ 90% | 20% (Y1-Y4), 15% (Y5), 5% (Y6) | 6 years |
| Key Chemical Synthesis-based | ≥ 70% | 20% flat | 5 years |
| Niche Chemical Synthesis-based | ≥ 70% | 20% flat | 5 years |
Fermentation-based KSMs/DIs (Target Segment 1): Penicillin G, 7-ACA (7-aminocephalosporanic acid), 6-APA (6-aminopenicillanic acid), erythromycin thiocyanate, clavulanic acid.
Fermentation-based APIs (Target Segment 2): rifampicin, tetracycline, vitamin B12, dexamethasone, betamethasone, ciprofloxacin, neomycin, gentamicin, streptomycin.
Chemical-synthesis KSMs/DIs/APIs (Target Segments 3-4): atorvastatin, losartan potassium, telmisartan, valsartan, levofloxacin, ofloxacin, ciprofloxacin hydrochloride, acyclovir, ritonavir, meropenem, levetiracetam, diclofenac sodium, ibuprofen, paracetamol.
The scheme has operated through multiple application rounds since 2020. DoP's most recent published application notice (26 November 2025) opens the 6th round, specifically inviting applications for products with unselected/lapsed slots — notably meropenem, ritonavir, and select fermentation-based products.
is among the largest sector-specific PLI commitments and the single largest discretionary subsidy targeting India's pharmaceutical manufacturing base.
India's ~70% bulk-drug import dependence on China — an exposure made acutely visible by COVID-19 supply-chain disruptions in H1 2020 (Chinese API export delays from Hubei/Zhejiang clusters).
with high domestic value-add floors (90% for fermentation, 70% for synthesis) — designed to reconstitute upstream KSM/DI capabilities India largely lost between 1995-2010 as Chinese fermentation capacity scaled.
most import-dependent essential APIs (penicillins, cephalosporins, vitamins, statins, antivirals) rather than broad "pharma" subsidies.
Severity is 4 rather than 5 because: (i) disbursement to date (~Rs 1,008 crore reported) is small relative to outlay; (ii) several selected applicants have surrendered slots due to economics of competing against Chinese fermentation incumbents on price; (iii) the scheme does not restrict Chinese API imports — it is a positive industrial-finance instrument, not a defensive trade measure.
The PLI Bulk Drugs scheme was approved by the Union Cabinet on 21 March 2020 alongside three companion measures:
1. PLI Scheme for Medical Devices (Rs 3,420 crore, separate gazette) 2. Promotion of Bulk Drug Parks Scheme (Rs 3,000 crore, 3 bulk-drug parks — Andhra Pradesh, Himachal Pradesh, Gujarat — providing common infrastructure) 3. Atmanirbhar Bharat Abhiyan broader self-reliance package
The 21 July 2020 gazette notification operationalised the bulk-drugs PLI. Scheme Guidelines were revised 29 October 2020, with multiple corrigendums issued through 2022-2026 to address product-level definitional issues and application-round mechanics.
This scheme is distinct from but complementary to the PLI Scheme for Pharmaceuticals (a separate, broader formulations-focused PLI notified 27 February 2021 with a Rs 15,000 crore outlay covering biopharmaceuticals, complex generics, patented drugs and drug intermediates). The bulk-drugs PLI is the upstream-KSM/API leg; the pharma PLI is the downstream formulations leg.
Public information from DoP and IFCI portal confirms multiple selections across the four target segments, including large Indian generics firms (Aurobindo Pharma, Lupin, Dr Reddy's, Cipla, Sun Pharma, Divi's, Biocon) and specialist API-focused players (Solara Active Pharma Sciences, Hikal, Aarti Drugs). Exact selection lists vary by round and product.
manufacturing capex corridor (Hyderabad-Visakhapatnam, Mumbai-Pune, Ahmedabad-Vadodara, Solan-Baddi).
via greenfield KSM/API capacity additions and incremental-sales incentive accrual.
precisely the fermentation and synthesis API categories where China holds 50-90% of global supply (e.g., 95% of penicillin G, 90% of paracetamol KSMs). Material impact requires 5-10 year build-out.
upstream creates optionality for US, EU and Japan formulations manufacturers sourcing APIs from Indian rather than Chinese suppliers — relevant to US BIOSECURE-style supply-chain de-risking discussions.
reviews suggest under-absorption in fermentation segments where Chinese cost competitiveness remains acute.
technology routes) without further public capital? The 6th application round (Nov 2025) reopening fermentation slots signals continued difficulty attracting commitments.
pharmaceutical proclamation (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation) and the EU pharma package (filed: 2025-12-11-eu-pharma-package-trilogue-agreement)? Indian APIs entering US/EU formulations supply chains may face derivative tariff treatment depending on how Section 232 final rules treat country of API origin vs country of finished-dose origin.